REGENXBIO (NASDAQ:RGNX) inks an agreement with Pfizer (NYSE:PFE) granting it a non-exclusive global license, with sublicense rights, to its NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of a rare inherited neurodegenerative movement disorder called Friedreich’s ataxia.
Under the terms of the deal, RGNX will receive an upfront payment, milestones and royalties on net sales. Specific financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.